Study wrapper · #968
Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
Al-Harbi FA, Alsaif AK, Almutairi AG, et al. Metabolism open. 2025.
DOI: 10.1016/j.metop.2025.100414PubMed: 41255585
Editor's note
A network meta-analysis and computational modeling exercise drawing on seven RCTs (5,786 participants) of amylin-pathway agents including cagrilintide and CagriSema. Findings are model-derived predictions rather than direct trial outcomes, so results should be read as hypothesis-generating. Relevant to the amylin drug class.
Plain-language abstract
This modeling study pooled seven trials of amylin-pathway therapies, including CagriSema and cagrilintide, to simulate comparative effectiveness for obesity and type 2 diabetes.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026